Edwards Lifesciences Corporation (EW): Price and Financial Metrics


Edwards Lifesciences Corporation (EW)

Today's Latest Price: $71.69 USD

1.22 (-1.67%)

Updated Oct 30 7:00pm

Add EW to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 142 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

EW Stock Summary

  • EW has a higher market value than 95.74% of US stocks; more precisely, its current market capitalization is $44,680,668,691.
  • With a one year PEG ratio of 1,800.09, Edwards Lifesciences Corp is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 97.94% of US stocks.
  • In terms of volatility of its share price, EW is more volatile than 93.07% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Edwards Lifesciences Corp, a group of peers worth examining would be PHG, ATVI, BSX, ILMN, and TEL.
  • EW's SEC filings can be seen here. And to visit Edwards Lifesciences Corp's official web site, go to www.edwards.com.

EW Stock Price Chart Interactive Chart >

Price chart for EW

EW Price/Volume Stats

Current price $71.69 52-week high $87.79
Prev. close $72.91 52-week low $51.51
Day low $70.92 Volume 3,131,454
Day high $72.81 Avg. volume 3,635,580
50-day MA $81.22 Dividend yield N/A
200-day MA $74.28 Market Cap 44.68B

Edwards Lifesciences Corporation (EW) Company Bio


Edwards Lifesciences provides products and technologies to treat structural heart disease and critically ill patients worldwide. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The company was founded in 1999 and is based in Irvine, California.

EW Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$71.69$6.38 -91%

Below please find a table outlining a discounted cash flow forecast for EW, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Edwards Lifesciences Corp ranked in the 10th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Edwards Lifesciences Corp, consider:

  • In the past 5.68 years, Edwards Lifesciences Corp has a compound free cash flow growth rate of -0.05%; that's higher than only 15.04% of free cash flow generating stocks in the Healthcare sector.
  • The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately just 7.08% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • EW's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 50.72% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-91%
1%-91%
2%-91%
3%-91%
4%-91%
5%-91%

VAR, BLFS, COO, LGND, and RGEN can be thought of as valuation peers to EW, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


EW Latest News Stream


Event/Time News Detail
Loading, please wait...

EW Latest Social Stream


Loading social stream, please wait...

View Full EW Social Stream

Latest EW News From Around the Web

Below are the latest news stories about Edwards Lifesciences Corp that investors may wish to consider to help them evaluate EW as an investment opportunity.

Edward Lifesciences: Examining Its Valuation And Fair Value

Due to the pandemic, Edward Lifesciences' (EW) sales were not as robust in 1H20 compared to recent quarters/years. As a result, management pulled back their guidance but the stock price remained fairly steady before its recent increase higher. Now, the stock price is up ~13% over a 1-year period. This...

Nick Perez on Seeking Alpha | September 18, 2020

Worldwide Tricuspid Valve Repair Devices Industry to 2024 - Players Include Abbott & Edwards Lifesciences Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Tricuspid Valve Repair Devices Market" report has been added to ResearchAndMarkets.com's offering. This report was developed using extensive primary and secondary research by the publisher's analysts. Data from proprietary databases, proprietary market reports, company reports, import/export databases, and secondary data sources on medical device markets were used to develop estimates of 2019 worldwide market size by product segment, ASPs, sales, and market

Business Wire | September 9, 2020

The Daily Biotech Pulse: Sanofi, GSK Begin Phase 1/2 Coronavirus Vaccine Study, Fulgent Strikes COVID-19 Testing Deal, New Data From Novavax

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Acutus Medical Inc (NASDAQ: AFIB ) Akouos Inc (NASDAQ: AKUS ) Avid Bioservices Inc (NASDAQ: CDMO ) ( reacted to strong quarterly results) BioLife Solutions Inc (NASDAQ: BLFS ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Edwards Lifesciences Corp (NYSE: EW ) Evogene Ltd (NASDAQ: EVGN ) Fortress Biotech (NASDAQ: FBIO ) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) (priced its 5.27-million-share common stock offering at $33 per share) Inspire Medical Systems Inc (NYSE: INSP ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Silk Road Medical Inc (NASDAQ: SILK ) Shockwave Medical Inc (NASDAQ: SWAV ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Twist Bioscience Corp ...

Benzinga | September 3, 2020

Global Transcatheter Mitral Valve Devices Market to 2024 - Featuring Cardiac Dimensions & Edwards Lifesciences Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Transcatheter Mitral Valve Devices Market" report has been added to ResearchAndMarkets.com's offering. This report was developed using extensive primary and secondary research by the publisher's analysts. Data from proprietary databases, proprietary market reports, company reports, import/export databases, and secondary data sources on medical device markets were used to develop estimates of 2019 worldwide market size by product segment, ASPs, sales, and mar

Business Wire | September 2, 2020

Global Cannula Market (2020 to 2025) - Featuring CONMED, Edwards Lifesciences & Medtronic Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Cannula Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering. The global cannula market grew at a CAGR of around 6% during 2014-2019. A cannula is a small hollow tube with a sharp and retractable inner core that is inserted into a vein, artery or body cavity to administer medication and draw off fluids. Several types of cannula are available for performing different proce

Business Wire | August 12, 2020

Read More 'EW' Stories Here

EW Price Returns

1-mo -9.23%
3-mo -8.57%
6-mo 3.93%
1-year -9.15%
3-year 111.23%
5-year 173.07%
YTD -7.81%
2019 52.31%
2018 35.90%
2017 20.29%
2016 18.64%
2015 24.01%

Continue Researching EW

Here are a few links from around the web to help you further your research on Edwards Lifesciences Corp's stock as an investment opportunity:

Edwards Lifesciences Corp (EW) Stock Price | Nasdaq
Edwards Lifesciences Corp (EW) Stock Quote, History and News - Yahoo Finance
Edwards Lifesciences Corp (EW) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9708 seconds.